Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

Conditions

• Renal Cell Carcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.

Key Dates

First listed

Jun 12, 2025

Start date

Jan 29, 2025

Status verified

Jun 2026

Primary completion

Jan 29, 2026

Completion

Jan 29, 2027

Study Design

Enrollment

20 participants (estimated)

Primary Outcome Measure

Torquetenovirus in numbers of copies/ml [ Time Frame: 24 months ]

Central Contacts

• Fabio Calabrò, Doctor
  +39 0652666271
  [email protected]

Find similar trials

Related Studies

• Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
  Enrolling By Invitation · National Institutes of Health Clinical Center (CC) · Bethesda, Maryland
• A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
  Recruiting · Beth Israel Deaconess Medical Center · Boston, Massachusetts
• A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
  PHASE3 · Recruiting · Xynomic Pharmaceuticals, Inc. · Phoenix, Arizona